Territorial Availability: Available through Bertin Technologies only in France
- Product Overview:
Leukemia inhibitory factor (LIF) is a cytokine and member of the IL-6 family with roles in cell growth and differentiation, bone metabolism, and inflammation.{52602} Mature LIF is a 180-amino acid peptide arranged as a four-helix bundle in an up-up-down-down configuration that is synthesized as a 202-amino acid precursor which is post-translationally processed to remove a 22-amino acid signaling sequence from its N-terminus. It is ubiquitously expressed and this expression is commonly upregulated under inflammatory conditions.{52603} LIF binds to its receptor LIFR? and recruits the IL-6 family common receptor gp130 to form a heterodimer and induce intracellular signaling via the JAK-STAT pathway.{52602,52604} Exogenous administration of LIF reduces the rate of deterioration in grip strength and slows progression of the forelimb deformity in the wobbler mouse model of amyotrophic lateral sclerosis (ALS).{52605} Intracerebroventricular administration of a recombinant adeno-associated viral vector encoding LIF reduces food intake and body weight gain in rats.{52606} Knockdown of Lif induces infertility in female mice.{52602} Cayman’s LIF (human, recombinant) protein can be used for cell-based assay applications. This protein consists of 180 amino acids, has a calculated molecular weight of 19.7 kDa, and a predicted N-terminus of Ser23 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 35.4 kDa due to glycosylation.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.